Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 9/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | CDC25B | P30305 | 1/20 | 0.63 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321911 | 0.87 | HCAR3 (1.00) | HCAR3CDC25BKMT2AMEN1 | |
| SCHEMBL27111058 | 0.87 | HCAR3 (0.58) | HCAR3HTTCDC25BPRKCIMAPT | |
| SCHEMBL8612192 | 0.85 | MAPT (0.57) | HCAR3HTTMAPTALDH1A1MAPK1 | |
| SCHEMBL2643864 | 0.85 | KMT2A (0.68) | HCAR3HTTMAPTALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL321637 | 0.85 | HCAR3 (0.97) | HCAR3CDC25BKMT2AMEN1 | |
| SCHEMBL506550 | 0.85 | HCAR3 (0.74) | HCAR3HTTCDC25BMAPTALDH1A1 | |
| SCHEMBL10665446 | 0.85 | HCAR3 (0.74) | HCAR3HTTCDC25BMAPTALDH1A1 | |
| SCHEMBL2253159 | 0.85 | HCAR3 (0.74) | HCAR3HTTCDC25BMAPTALDH1A1 | |
| SCHEMBL29793669 | 0.85 | KMT2A (0.68) | HCAR3HTTMAPTALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL18813442 | 0.84 | HCAR3 (0.72) | HCAR3HTTCDC25BMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | disclosed |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-01-12 | — | — | US | disclosed |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2020-05-14 | — | — | US | disclosed |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| EP-1718608-A1 | VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20050222236-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080388-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
| EP-0260744-B1 | (1H-IMIDAZOL-1-YLMETHYL) SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
| US-4859684-A | (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-08-22 | — | — | US | disclosed |
| EP-0260744-A2 | (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-03-23 | — | — | EP | disclosed |
| US-4344957-A | Benz-acyl-benzimidazole derivatives and antiallergic compositions | CIBA-GEIGY CORPORATION (US) | 1982-08-17 | — | — | US | disclosed |
| US-4213993-A | ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1980-07-22 | — | — | US | disclosed |
| US-4141982-A | ANTIALLERGENS | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | HCAR3 1803/4885HTT 1101/4885CDC25B 4293/4885 |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | HCAR3 1803/4885HTT 1101/4885CDC25B 4293/4885 |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | HCAR3 1803/4885HTT 1101/4885CDC25B 4293/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | HCAR3 1984/4885HTT 986/4885CDC25B 4264/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | HCAR3 1803/4885HTT 1101/4885CDC25B 4293/4885 |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GOT2, GLS2, PYGL | HCAR3 1122/4885HTT 3101/4885CDC25B 4421/4885 |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, UACA | HCAR3 1540/4885HTT 703/4885CDC25B 4377/4885 |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GOT2, GLS2, PYGL | HCAR3 1122/4885HTT 3101/4885CDC25B 4421/4885 |
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | HCAR3 4801/4885HTT 1501/4885CDC25B 2566/4885 |
| US-20050222236-A1 | Viral polymerase inhibitors | POLR2A, POLR1E, RPP30 | HCAR3 4801/4885HTT 1501/4885CDC25B 2566/4885 |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, UACA | HCAR3 1540/4885HTT 703/4885CDC25B 4377/4885 |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | HCAR3 1803/4885HTT 1101/4885CDC25B 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.